[Form 4] ANI Pharmaceuticals, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Thomas Haughey, a director of ANI Pharmaceuticals, Inc. (ANIP), reported the sale of 19,341 shares of the company's common stock on 08/12/2025 at a weighted-average price of $85.93 per share, according to this Form 4 filing. After the sale, Haughey beneficially owned 36,521 shares. The filing indicates the shares were sold in multiple trades at prices ranging from $84.50 to $87.16, and the form was signed by attorney-in-fact Meredith W. Cook on 08/14/2025.

The report is a standard Section 16 disclosure showing an insider disposition; it provides the exact quantities, price range, and resulting beneficial ownership recorded on the form.

Positive

• Timely and complete disclosure of insider sale with transaction date, price range, weighted-average price, and post-sale beneficial ownership.
• Exact figures provided: 19,341 shares sold, weighted-average price $85.93, 36,521 shares beneficially owned after sale.

Negative

• Insider disposition of 19,341 shares represents a meaningful sale by a director which could be viewed negatively by some investors.
• No disclosure of sale purpose or 10b5-1 plan within the form, so the rationale for the trades is not provided in this document.

Insights

Securities Analyst

TL;DR: Director disposition of 19,341 shares at $85.93 weighted average, leaving 36,521 shares beneficially owned; a routine Section 16 sale disclosure.

The filing documents a sizeable but defined sale by a board director executed in multiple trades between $84.50 and $87.16, producing a weighted-average price of $85.93. The remaining beneficial ownership is stated precisely. From a market-impact perspective, the filing provides clear, required transparency; it does not include any commentary about the purpose of the sale or related trading plans, so no additional context is provided within the document itself.

Corporate Governance Expert

TL;DR: Timely, properly executed Form 4 shows a director sale and remaining holdings; disclosure meets Section 16 requirements.

The report identifies Thomas Haughey as a director and reports the transaction codes and post-transaction holdings as required. The explanation states the sale occurred in multiple trades with a disclosed price range and weighted-average price, and the form is signed by an attorney-in-fact. The disclosure is procedurally complete for an insider disposition; the document contains no information about any 10b5-1 plan or other rationale for the sale.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HAUGHEY THOMAS

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

210 MAIN STREET WEST

(Street)

BAUDETTE MN 56623

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/12/2025		S		19,341	D	$85.93(1)	36,521	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold in multiple trades at prices ranging from $84.50 to $87.16. The price reported above reflects the weighted average sales price.

Remarks:

	/s/ Thomas Haughey, by attorney-in-fact Meredith W. Cook	08/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Thomas Haughey report for ANIP?

He reported the sale of 19,341 shares of ANI Pharmaceuticals common stock on 08/12/2025.

At what price were the ANIP shares sold in the Form 4?

The shares were sold in multiple trades at prices ranging from $84.50 to $87.16, with a weighted-average price of $85.93.

How many ANIP shares does Thomas Haughey beneficially own after the reported sale?

The Form 4 shows he beneficially owned 36,521 shares following the reported transaction.

What role does Thomas Haughey hold at ANI Pharmaceuticals per the filing?

The filing identifies Thomas Haughey as a Director of ANI Pharmaceuticals, Inc.

Was the Form 4 properly signed and when was it filed?

The form includes a signature by attorney-in-fact Meredith W. Cook dated 08/14/2025 as the reported filing date on the document.